Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma (Q33875560)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1 reference

based on heuristic

inferred from title

head and neck squamous cell carcinoma

1 reference

based on heuristic

inferred from title

15

object named as

Fadlo R Khuri

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

author name string

Ning Jiang

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Dongsheng Wang

2

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Zhongliang Hu

3

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Hyung Ju C Shin

4

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Guoqing Qian

5

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Mohammad Aminur Rahman

6

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Hongzheng Zhang

7

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

A R M Ruhul Amin

8

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Sreenivas Nannapaneni

9

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Xiaojing Wang

10

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Zhengjia Chen

11

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Gabriela Garcia

12

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Gavin MacBeath

13

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Dong M Shin

14

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Jun Ma

16

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Zhuo G Chen

17

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Nabil F Saba

18

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

publication date

18 April 2014

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Molecular Cancer Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1826-1836

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Oropharyngeal cancers: relationship between epidermal growth factor receptor alterations and human papillomavirus status

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Enhanced radiation sensitivity in HPV-positive head and neck cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention against head and neck cancer-containing HPV16 cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Advances in Targeting HER3 as an Anticancer Therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

The pivotal role of integrin β1 in metastasis of head and neck squamous cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Future directions in research, treatment and prevention of HPV-related squamous cell carcinoma of the head and neck

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Resistance to EGFR-targeted therapy: a family affair

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Targeting ErbB3-mediated stromal-epithelial interactions in pancreatic ductal adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Enhanced anti-tumor activity by the combination of the natural compounds (-)-epigallocatechin-3-gallate and luteolin: potential role of p53

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Alteration of microRNA profiles in squamous cell carcinoma of the head and neck cell lines by human papillomavirus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Cancer statistics, 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Platinum-based chemotherapy plus cetuximab in head and neck cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Clinical implications of human papillomavirus in head and neck cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Ribosomal protein S6 phosphorylation: from protein synthesis to cell size.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Expression of protein tyrosine kinases in head and neck squamous cell carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Global cancer statistics, 2002

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

5 July 2018

The road to resistance: EGFR mutation and cetuximab.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

29 October 2018

Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

29 October 2018

Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

29 October 2018

Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

29 October 2018

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090261

29 October 2018

Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/24748655

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1535-7163.MCT-13-1093

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33875560&oldid=1533768186"